晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.011

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (4): 351-355.doi: 10.11904/j.issn.1002-3070.2022.04.011

晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展

董琳¹, 刘欣¹ 综述, 鲁海玲^1,2 审校

1.哈尔滨医科大学附属肿瘤医院肿瘤内科(哈尔滨 150081);
2.哈尔滨医科大学附属第一医院肿瘤科

收稿日期:2022-05-27 修回日期:2022-06-30 出版日期:2022-08-28 发布日期:2022-08-29
通讯作者: 鲁海玲,E-mail:luhailing2004@163.com
作者简介:董琳,女,(1995-),硕士研究生,从事乳腺癌及肺癌耐药机制的相关研究。
基金资助:
1.北京医学奖励基金会(编号:YXJL-2021-0678-0664);2.国家癌症中心攀登基金(编号:NCC201808B018)

Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer

DONG Lin¹, LIU Xin¹, LU Hailing^1,2

1. Department of Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;
2. Department of Oncology,The First Affiliated Hospital of Harbin Medical University

Received:2022-05-27 Revised:2022-06-30 Online:2022-08-28 Published:2022-08-29

摘要/Abstract

摘要： 近年来,转移性或局部晚期非小细胞肺癌的治疗取得了较大的进展,特别是在一线治疗或治疗后出现进展的患者。通过联合治疗提高疗效已成为该领域的主要研究方向,对于没有驱动基因突变或对靶向治疗无效的患者,这种探索尤为迫切。有证据表明促血管生成因子具有免疫抑制活性,这使得研究人员开始评估抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的潜在协同作用。本文就抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的理论基础及临床研究进行综述。

关键词: 非小细胞肺癌, 抗血管生成治疗, 免疫检查点抑制剂

Abstract: In recent years,great progress has been made in the treatment of metastatic or locally advanced non-small cell lung cancer,especially for patients who have progressed after first-line therapy or treatment.Improving efficacy through combination therapy has become the main direction in this field,and this exploration is particularly urgent for patients who do not have drive gene mutations or are ineffective against targeted therapy.Evidence that pro-angiogenic factors have immunosuppressive activity led researchers to evaluate potential synergistic effects of anti-angiogenic drugs in combination with immune checkpoint inhibitors in advanced non-small cell lung cancer.This article reviews the theoretical basis and clinical research of anti-angiogenic drugs combined with immune checkpoint inhibitors in the treatment of advanced non-small cell lung cancer.

Key words: Non-small cell lung cancer, Anti-angiogenic therapy, Immune checkpoint inhibitors

中图分类号:

R734.2

董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.

DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer[J]. Journal of Practical Oncology, 2022, 36(4): 351-355.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/351

参考文献

1 Topalian SL,Hodi FS,Brahmer JR,et al.Five-year survival and correlates among patients with advanced melanoma,renal cell carcinoma,or non-small cell lung cancer treated with nivolumab[J].JAMA Oncol,2019,5(10):1411-1420.
2 Sharma P,Hu-Lieskovan S,Wargo JA,et al.Primary,adaptive,and acquired resistance to cancer immunotherapy[J].Cell,2017,168(4):707-723.
3 Jenkins RW,Barbie DA,Flaherty KT.Mechanisms of resistance to immune checkpoint inhibitors[J].Br J Cancer,2018,118(1):9-16.
4 Huang Y,Goel S,Duda DG,et al.Vascular normalization as an emerging strategy to enhance cancer immunotherapy[J].Cancer Res,2013,73(10):2943-2948.
5 Ramjiawan RR,Griffioen AW,Duda DG.Anti-angiogenesis for cancer revisited:Is there a role for combinations with immunotherapy?[J].Angiogenesis,2017,20(2):185-204.
6 Saharinen P,Eklund L,Pulkki K,et al.Vegf and angiopoietin signaling in tumor angiogenesis and metastasis[J].Trends Mol Med,2011,17(7):347-362.
7 Mennitto A,Huber V,Ratta R,et al.Angiogenesis and immunity in renal carcinoma:Can we turn an unhappy relationship into a happy marriage?[J].J Clin Med,2020,9(4):930.
8 Kim HJ,Ji YR,Lee YM.Crosstalk between angiogenesis and immune regulation in the tumor microenvironment[J].Arch Pharm Res,2022,45(6):401-416.
9 Hack SP,Zhu AX,Wang Y.Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-l1 pathways:Challenges and opportunities[J].Front Immunol,2020,11:598877.
10 Lee WS,Yang H,Chon HJ,et al.Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity[J].Exp Mol Med,2020,52(9):1475-1485.
11 Rahma OE,Hodi FS.The intersection between tumor angiogenesis and immune suppression[J].Clin Cancer Res,2019,25(18):5449-5457.
12 Reck M,Mok TSK,Nishio M,et al.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer(impower150):Key subgroup analyses of patients with egfr mutations or baseline liver metastases in a randomised,open-label phase 3 trial[J].Lancet Respir Med,2019,7(5):387-401.
13 Socinski MA,Jotte RM,Cappuzzo F,et al.Atezolizumab for first-line treatment of metastatic nonsquamous nsclc[J].N Engl J Med,2018,378(24):2288-2301.
14 Lam TC,Tsang KC,Choi HC,et al.Combination atezolizumab,bevacizumab,pemetrexed and carboplatin for metastatic egfr mutated nsclc after tki failure[J].Lung Cancer,2021,159:18-26.
15 Sugawara S,Lee JS,Kang JH,et al.Nivolumab with carboplatin,paclitaxel,and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer[J].Ann Oncol,2021,32(9):1137-1147.
16 Rizvi NA,Antonia SJ,Shepherd FA,et al.Nivolumab(anti-PD-1;bms-936558,ono-4538)maintenance as monotherapy or in combination with bevacizumab(bev)for non-small cell lung cancer(nsclc)previously treated with chemotherapy[J].Int J Radiat Oncol,2014,90(5):32.
17 Kanda S,Goto K,Shiraishi H,et al.Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer:a four arms phase Ⅰb study[J].Ann Oncol,2016,27(12):2242-2250.
18 Gadgeel SM,Stevenson JP,Langer CJ,et al.Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer:phase 1 cohorts from the keynote-021 study[J].Lung Cancer,2018,125:273-281.
19 Herbst RS,Arkenau HT,Santana-Davila R,et al.Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer,gastro-oesophageal cancer,or urothelial carcinomas(jvdf):A multicohort,non-randomised,open-label,phase 1a/b trial[J].Lancet Oncol,2019,20(8):1109-1123.
20 Herbst RS,Arkenau HT,Bendell J,et al.Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naïve nsclc[J].J Thorac Oncol,2021,16(2):289-298.
21 Lin B,Song X,Yang D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of vegfr2,pdgfrβ and fgfr1[J].Gene,2018,654:77-86.
22 Zhou CC,Gao GH,Ren SX,et al.Efficacy of PD-1 monoclonal antibody shr-1210 plus apatinib in patients with advanced non-squamous nsclc with wild-type egfr and alk[J].J Clin Oncol 2019,37:9112.
23 Zhou C,Wang Y,Zhao J,et al.Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous nsclc previously treated with chemotherapy[J].Clin Cancer Res,2021,27(5):1296-1304.
24 Gao G,Wang Y,Ren S,et al.1267p efficacy of camrelizumab(shr-1210)plus apatinib as second-line treatment for advanced squamous nsclc[J].Ann Oncol,2020,31:819.
25 Taylor MH,Lee CH,Makker V,et al.Phase Ⅰb/Ⅱ trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma,endometrial cancer,and other selected advanced solid tumors[J].J Clin Oncol,2020,38(11):1154-1163.
26 Nishio M,Peled N,Zer A,et al.1313p phase Ⅲ leap-006 safety run-in(part 1):1l pembrolizumab(pembro)+ chemotherapy(chemo)with lenvatinib(len)for metastatic nsclc[J].Ann Oncol,2020,31:848-849.
27 Chu T,Zhong R,Zhong H,et al.Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced nsclc[J].J Thorac Oncol,2021,16(4):643-652.

[1]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[2]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[3]	张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.
[4]	刘金爽, 张文静, 黎清炜, 李志伟. 免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 49-53.
[5]	罗雯, 贾莉, 张佳文, 王冬杰, 孔英君. circRNA MYO1C对肺癌细胞自噬和肿瘤干细胞分化的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 500-505.
[6]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[7]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[8]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[9]	汪叶, 尚乃舰. 影像组学在非小细胞肺癌诊疗中的应用进展[J]. 实用肿瘤学杂志, 2021, 35(5): 485-488.
[10]	王俊美, 潘慧卿, 李婧铱, 贾迪, 赵炜明, 吕昌莲. MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2021, 35(3): 243-247.
[11]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[12]	尹蕾, 杨旭东, 杨悦, 牛星鉴, 周晓平, 姬宏飞, 王一然. 中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J]. 实用肿瘤学杂志, 2021, 35(2): 117-124.
[13]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[14]	董程(综述),段勇(审校). Dickkopf家族蛋白在非小细胞肺癌中的作用机制和治疗应用的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 64-68.
[15]	石琳娜, 隋红. 原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J]. 实用肿瘤学杂志, 2020, 34(6): 560-564.

晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展

Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价